Literature DB >> 19031955

Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.

Judit Müller1, Judit Kralovánszky, Vilmos Adleff, Eva Pap, Krisztina Németh, Viktor Komlósi, Gábor Kovács.   

Abstract

BACKGROUND: High-dose methotrexate (HD-MTX) is one of the most important agents in the therapy of osteosarcoma (OSC). Acute and delayed toxicities still constitute clinical problems. Methylenetetrahydrofolate reductase (MTHFR) has a key role in the folate cycle. In case of homozygosity of the 677C-->T polymorphism, treatment with antimetabolites, such as MTX, can cause additional toxicity. CASE REPORT: In the present work, we describe the case of a 10-year-old boy with OSC. After the first HD-MTX infusion (12 g/m2/6 h) acute neurological disturbances were detected followed by severe hepatotoxicity. Plasma concentrations of MTX and 7-OH-MTX showed delayed clearance. Calcium folinate was administered to the patient until +186 hours. Tha patient was homozygous for the 677 polymorphism and wild-type for the 1298 polymorphism of the MTHFR gene.
CONCLUSION: We hypothesize that MTX toxicity can be explained by the association between homozygosity of the MTHFR C677T polymorphism causing disturbances in the folate status and thus an enhanced vulnerability of the central nervous system to antimetabolites and to the prolonged MTX exposure due to delayed MTX clearance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19031955

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Prevalence and management of methotrexate-induced neurotoxicity in pediatric patients with osteosarcoma: a single-center experience.

Authors:  Yair Peled; Dror Levin; Shelly Shiran; Michal Manisterski; Rachel Shukrun; Ronit Elhasid
Journal:  Int J Clin Oncol       Date:  2022-05-31       Impact factor: 3.850

Review 2.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 3.  Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.

Authors:  Claudia Maria Hattinger; Maria Pia Patrizio; Silvia Luppi; Massimo Serra
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

4.  More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate.

Authors:  Lu Xie; Wei Guo; Yi Yang; Tao Ji; Jie Xu
Journal:  Oncotarget       Date:  2017-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.